Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.
Kevin E. Noonan
Advertisement
Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP.
Articles by Kevin E. Noonan
A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.
Advertisement
Latest Updated Articles
Biosimilar Names Prove Difficult to DefineMarch 1st 2017
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
4
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
5